This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
biotechs marijuana medical pot-stocks
TLRY vs. CRLBF: Which Cannabis Player Offers Greater Upside?
by Sridatri Sarkar
Tilray Brands' global expansion and strong Canadian momentum spotlight its edge as investors weigh upside against Cresco Labs' slower growth.
marijuana medical
Cresco Labs Expands Operations Beyond U.S.: How to Play the Stock?
by Sundeep Ganoria
CRLBF's move into Germany opens a new growth path as it navigates U.S. pricing pressure and rising competition in its core market.
marijuana medical
Tilray Brands Extends Profit Momentum With Strong Q1 Results
by Sridatri Sarkar
TLRY posts a sharp profitability turnaround in Q1 as cost control, efficiency gains and portfolio optimization boost results.
marijuana medical
Should You Buy, Hold or Sell CGC Stock Post Q2 Earnings Release?
by Sundeep Ganoria
Canopy Growth's narrower loss, rising Canadian sales and improving margins signal progress in its turnaround, even as competition and global headwinds persist.
marijuana medical
Tilray Brands Extends Global Reach With Key Approvals and Launches
by Sridatri Sarkar
TLRY expands its global medical cannabis footprint with key launches and approvals across Panama, Germany, Italy and Australia.
marijuana
Cannabis Stock Tilray Brands Skyrockets 94.5%: Time to Buy, Sell or Hold?
by Sridatri Sarkar
TLRY's 94.5% surge, record fiscal Q1 revenues, and expanding medical cannabis footprint fuel optimism amid global challenges.
marijuana medical
Should You Buy, Hold or Sell VRNO Stock Post Q3 Earnings Release?
by Sundeep Ganoria
Verano's Q3 results show pressure from U.S. price competition and margin compression, but cost cuts and new products signal longer-term optimism.
marijuana medical
Cannabis Stock VFF Soars Over 300% YTD: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Village Farms' surge reflects its pivot to a pure-play cannabis model, record profitability and a confident $10M share buyback.
marijuana medical
How to Play Aurora Cannabis Stock Amid Renewed Legalization Hopes?
by Sundeep Ganoria
Aurora Cannabis gains 21% as its medical segment fuels revenue and margin growth, even as recreational sales drag.
marijuana medical